Francois Nader | Chairman
Acceleron Pharma

Francois Nader, Chairman, Acceleron Pharma

Francois Nader, MD, is currently the chairman of Acceleron Pharma and a leading value builder in the biopharma industry.  He was President, Chief Executive Officer and Executive Director of NPS Pharma from 2008 to 2015, when the company was acquired by Shire for $5.2B.  During his tenure as CEO, Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases.  He was recognized as the Ernst and Young National Life Science Entrepreneur of the Year® in 2013. Dr. Nader currently serves as chairman of the board of directors of Acceleron Pharma (NASDAQ: XLRN) and board director of Alexion Pharmaceuticals (NASDAQ: ALXN), Clementia Pharmaceuticals (NASDAQ: CMTA) and ArRETT Neuroscience.
Before NPS, Dr. Nader was a venture partner at Care Capital. Prior, he served on the North America Leadership Team of Aventis and its predecessor companies holding a number of executive positions including senior vice-president, integrated healthcare markets and North America medical and regulatory affairs. Previously, he led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc.
Dr. Nader is a recognized leader in industry and philanthropic organizations. He is the vice president of the Jesra Foundation, a trustee of the New Jersey Chamber of Commerce and sits on the Advisory Board of the Open Future Institute. He is a past chairman of BioNJ, New Jersey’s biotechnology trade organization and has served on the board of the Biotechnology Industry Organization (BIO), the national industry body, NPS Pharma (NASDAQ: NPSP), Advanced Accelerator Applications (NASDAQ: AAAP), Baxalta (NYSE: BXLT), Trevena (NASDAQ: TRVN) and Noven (NASDAQ: NOVN).
Dr. Nader earned his French Doctorate in Medicine from St. Joseph University in Lebanon and his Physician Executive MBA from the University of Tennessee.

Appearances:



World Orphan Drug Congress USA 2018 - Conference Day One @ 17:20

Keynote panel: How rare disease companies are ramping up innovation to boost orphan drug development and patient centricity

  • Incorporating patients in the drug development process and working towards commercial viability- how to fully engage? 
  • How do you view disruptive therapies such as (gene therapy/gene editing) impacting the broader orphan disease development paradigm? How are you innovating within your company?
  • Responding to the changes in the political, regulatory and reimbursement landscape while guiding the direction of rare disease companies 
  • How to achieve industry collaboration and idea exchanges that can better serve the patient community? 

back to speakers